Pensacola, FL – June 8, 2020 – ActiGraph, a leading provider of medical-grade wearable physical activity and sleep monitoring solutions for the global scientific community, has promoted Jeremy Wyatt to Chief Executive Officer, effective June 1, 2020, following its recent investment from global private equity firm, ArchiMed. ActiGraph’s former CEO, Jeff Arnett, has stepped down to assume a new role as Senior Vice President of Corporate Development and Strategy with a primary focus on strategic growth, including new solutions, markets, and partnerships. Arnett also occupies a seat on the company’s Board of Directors.
“With our recent investment, ActiGraph is going through an exciting transition and there is no one more capable of leading this company than Jeremy Wyatt,” said former CEO Jeff Arnett. “Having worked alongside Jeremy for twenty years, I have every confidence that his breadth and depth of experience and commitment to ActiGraph’s mission will drive our future growth and success.”
“I’m grateful for the values that Jeff Arnett has helped to instill in this company,” said Jeremy Wyatt. “We have a really incredible team of people here, and I’m honored to have the opportunity to lead in this next phase.”
Wyatt has been with ActiGraph since its inception in 2004. During this time, he has held multiple hardware and software engineering leadership roles and most recently served as the company’s President and Chief Operations Officer since early 2019. In his new role as CEO, Wyatt is responsible for the alignment of the company’s technology, product design, process development, and corporate strategy to drive growth across new and existing markets.
About ActiGraph – www.actigraphcorp.com – ActiGraph’s mission is to help people live longer, better lives. We do that by providing our clients with high resolution, digital data that can be used to explain, influence, and predict human health outcomes. As a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community, ActiGraph’s FDA-cleared wearable activity monitors and robust data management and analytics platform have been used extensively to quantify human movement in academic and population health research for two decades. More recently, ActiGraph technology solutions have been widely adopted by pharmaceutical and life sciences organizations seeking to capture and monitor real-world physical activity, mobility, and sleep behavior for patients enrolled in clinical trials.